Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40292-021-00439-9 http://scihub22266oqcxt.onion/10.1007/s40292-021-00439-9 33635533!7908946!33635533     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       High+Blood+Press+Cardiovasc+Prev 2021 ; 28 (2): 129-139 Nephropedia Template TP {{tp|p=33635533|t=2021. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update |pdf=|usr=}}{{33635533}} gab.com Text Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update JO: High Blood Press Cardiovasc Prev http://www.kidney.de/pget.php?&tw=1&pmid=33635533 #FOAvip Ever since its outbreak, Corona Virus Disease 2019(COVID-19) caused by SARS-CoV-2 has affected more than 26 million individuals in more than 200 countries. Although the mortality rate of COVID-19 is low, but several clinical studies showed, patients with diabetes mellitus (DM) or other major complication at high risk of COVID-19 and reported more severe disease and increased fatality. The angiotensin-converting-enzyme 2 (ACE2), a component of renin-angiotensin-system (RAS); acts on ACE/Ang-II/AT1recptor axis, and regulates pathological processes like hypertension, cardiac dysfunction, Acute Respiratory Distress Syndrome (ARDS) etc. The progression of T2DM and hypertension show decreased expression and activity of ACE2. There are several treatment strategies for controlling diabetes, hypertension, etc; like ACE2 gene therapies, endogenous ACE2 activators, human recombinant ACE2 (hrACE2), Angiotensin-II receptor blockers (ARBs) and ACE inhibitors (ACEi) medications. ACE2, the receptors for SARS-CoV2, facilitates virus entry inside host cell. Clinicians are using two classes of medications for the treatment of COVID-19; one targets the SARS-CoV-2-ACE2 interaction, while other targets human immune system. The aim of this review is to discuss the role of ACE2 in diabetes and in COVID-19 and to provide an analysis of data proposing harm and benefit of RAS inhibitor treatment in COVID-19 infection as well as showing no association whatsoever. This review also highlights some candidate vaccines which are undergoing clinical trials. Twit Text FOAVip Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update ????High Blood Press Cardiovasc Prev http://www.kidney.de/pget.php?&tw=1&pmid=33635533 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33635533 #FOAvip English Wikipedia <ref>{{Cite pmid|33635533}}</ref> Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update #MMPMID33635533 Shukla AK; Banerjee M High Blood Press Cardiovasc Prev 2021[Mar]; 28 (2): 129-139 PMID33635533show ga Ever since its outbreak, Corona Virus Disease 2019(COVID-19) caused by SARS-CoV-2 has affected more than 26 million individuals in more than 200 countries. Although the mortality rate of COVID-19 is low, but several clinical studies showed, patients with diabetes mellitus (DM) or other major complication at high risk of COVID-19 and reported more severe disease and increased fatality. The angiotensin-converting-enzyme 2 (ACE2), a component of renin-angiotensin-system (RAS); acts on ACE/Ang-II/AT1recptor axis, and regulates pathological processes like hypertension, cardiac dysfunction, Acute Respiratory Distress Syndrome (ARDS) etc. The progression of T2DM and hypertension show decreased expression and activity of ACE2. There are several treatment strategies for controlling diabetes, hypertension, etc; like ACE2 gene therapies, endogenous ACE2 activators, human recombinant ACE2 (hrACE2), Angiotensin-II receptor blockers (ARBs) and ACE inhibitors (ACEi) medications. ACE2, the receptors for SARS-CoV2, facilitates virus entry inside host cell. Clinicians are using two classes of medications for the treatment of COVID-19; one targets the SARS-CoV-2-ACE2 interaction, while other targets human immune system. The aim of this review is to discuss the role of ACE2 in diabetes and in COVID-19 and to provide an analysis of data proposing harm and benefit of RAS inhibitor treatment in COVID-19 infection as well as showing no association whatsoever. This review also highlights some candidate vaccines which are undergoing clinical trials. |*COVID-19 Drug Treatment[MESH] |Angiotensin Receptor Antagonists/adverse effects/*therapeutic use[MESH] |Angiotensin-Converting Enzyme 2/*antagonists & inhibitors/metabolism[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use[MESH] |Animals[MESH] |Antihypertensive Agents/therapeutic use[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Blood Pressure/drug effects[MESH] |COVID-19 Vaccines/therapeutic use[MESH] |COVID-19/enzymology/virology[MESH] |Diabetes Mellitus, Type 2/*drug therapy/enzymology/physiopathology[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |Hypertension/drug therapy/enzymology/physiopathology[MESH] |Patient Safety[MESH] |Renin-Angiotensin System/*drug effects[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |SARS-CoV-2/*drug effects/genetics/pathogenicity[MESH] |Treatment Outcome[MESH]Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitor(epmc).pdf DeepDyve Pubget Overpricing